Publications List - Biology (2009 - 2014)

MOST RECENT (2009 - 2014)

2014

  1. Eadie LN, Hughes TP, White DL. The Interaction of Efflux Transporters, ABCB1 and ABCG2, with Imatinib, Nilotinib and Dasatinib. 2014. Clinical Pharmacology and Therapeutics 95(3): 294-306. IF: 6.85
  2. Kok CH, Leclercq T, Watkins DB, Saunders V, Wang J, Hughes TP, White DL. Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. 2014. Leukemia 28(3): 702-5. IF: 10.16
  3. Nievergall, E, Ramshaw, HS, Yong ASM, Biondo M, Vairo S, Lopez, AL, Hughes TP, White DL, Hiwase D. Monoclonal antibody targeting of IL-3 receptor effectively depletes CML progenitors and stem cells. 2014. Blood 123(8): 1218-1228. IF: 9.06
  4. Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, White DL. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death on chronic myeloid leukemia. 2014. Leukemia [Epub ahead of print]. IF: 10.16
  5. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. 2014. Blood 124(1): 153-5. IF: 9.06
  6. Roberts KG*, Li Y*, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Shann-Chen C, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen I-M, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui C-H, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable Kinase Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. 2014. New England Journal of Medicine 371:1005-1015. IF: 54.42
  7. Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mulligan CG, Hughes TP, White DL. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. 2014. Leukemia [Epub ahead of print]. IF: 10.16
  8. Bartley PA, Latham S, Budgen B, Ross DM, Hughes E, Branford S, White DL, Hughes TP, Morley AA. A DNA-qPCR method suitable for routine monitoring of low levels of minimal residual disease inchronic myeloid leukemia. 2014. The Journal of Molecular Diagnostics [Accepted]. IF: 3.95
  9. Lu L, Saunders V, Leclercq T, Hughes TP, White DL. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. 2014. Leukemia [Accepted]. IF: 10.16
  10. Yeung DT, Osborn MP, White DL, Branford S, Prime J, Herschtal A, Slader C, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer A, Filshie R, Arthur CK, Kwan YL, Trottman J, Forsyth CJ, Taper J, Ross DM, Tam C, Dunster K, Mills AK, Grigg A, Hughes TP. TIDEL-II: frontline use of Imatinib in CML with Early Switch to Nilotinib for Failure to Achieve Time-Dependent Molecular Targets. On behalf of the ALLG. 2014. Blood [Epub ahead of print]. IF: 9.06

2013

  1. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. 2013. Hematologica 98(2): 193-200 IF: 5.94
  2. Eadie LN, Saunders VA, Hughes TP, White DL. The Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. 2013. Leukaemia and Lymphoma 54(3): 569-78 IF: 2.3
  3. Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino ACW, Pitson S, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. 2013. PLOS Biology 11(3): doi 10.1371 IF: 12.69
  4. Parker M, Dhagat U, Broughton SE, Nero T, Hughes TP, Ekert P, Sandow J, D’Andrea R, Perugini M, Kan W, Lopez A. Signaling by the <beta>c family of cytokines. 2013. Cytokine and Growth Factor Reviews 24:189-201 IF: 8.83
  5. Schafranek L, Leclercq TM, White DL, Hughes TP. Clarithromycin Enhances Dasatinib-Induced Cell Death in CML cells, by Inhibition of Late Stage Autophagy. 2013. Leukemia & Lymphoma 54(1):198-201. IF: 2.3
  6. White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. 2013. Leukemia 27(5):1201-1204 IF: 10.16
  7. Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP. Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. 2013. Haematologica 98(6):896-900 IF: 5.94
  8. Kok CH, Watkins DB, Leclercq TM, D'Andrea RJ, Hughes TP, White DL. Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation. 2013. Leukemia 27(6): 1427-30IF: 10.16
  9. Ross DM, O'Hely M, Bartley PA, Dang P, Score J, Goyne JM, Sobrinho-Simoes M, Cross NC, Melo JV, Speed TP, Hughes TP, Morley AA. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. 2013. Leukemia 27(10): 2105-2107 IF: 10.16
  10. Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. 2013. BMC Cancer 13(1):173 IF: 3.33
  11. Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF. Signalling by the βc family of cytokines. 2013. Cytokine Growth Factor Reviews 24(3):189-201 IF: 8.83
  12. Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. 2013. PLoS Biology 11(3) DOI: 10.1371/journal.pbio.1001515 IF: 12.69
  13. Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, Branford S. BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. 2013. British Journal of Cancer 109(6): 1593-1598 IF: 4.94
  14. Watkins DB, Hughes TP, White DL, D'Andrea RJ. NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. 2013. Leukemia 27(2): 489-490 IF: 10.16
  15. Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Valganon M, Nteliopoulos G, White DL, Marin D, Hedgley C, O’Brien S, Clark R, Goldman J, Szydlo R, Apperley J, Foroni L. A common novel splice variant in hOCT1 exon 7 is associated with impaired responses to imatinib in patients with Chronic Myeloid Leukaemia. 2013. British Journal of Haematology 163(5):631-639 IF: 4.94

2012

  1. Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D'Andrea RJ, White DL. Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. 2012. British Journal of Cancer 106:1772-1778 IF: 2.3
  2. Branford S, Yeung DT, Prime JA, Choi S-Y, Bang J-H, Park JE, Kim D-W, Ross DM, Hughes TP. BCR-ABL1 doubling-times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold-rise: implications for monitoring and management. 2012. Blood 119:4264-4271 IF: 9.06
  3. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second line kinase inhibitors in chronic myeloid leukaemia patients with multiple low level mutations, irrespective of their resistance profile. 2012. Blood 119:2234-2238 IF: 9.06
  4. Blake S, Lyons AB, Hughes TP. Drug interaction studies evaluating T cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. 2012. Experimental Haematology 40(8):612-621 IF: 2.91
  5. White DL, Brown AL, D'Andrea RJ, Rice AM. Unraveling the “Known Unknowns”: Lessons and Reflections from the New Directions in Leukemia Research 2012 Conference. 2012. Cancer Research 72(17):4300-4303. IF: 8.65
  6. White DL, Hughes TP. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. 2012. Journal of Clinical Oncology 30:1144-1145 IF: 18.04
  7. White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. 2012. Haematologica 97:907-914 IF: 5.94
  8. Hiwase DK, Hughes TP. Sudden blast crisis in chronic myeloid leukaemia treated with tyrosine kinase inhibitors. 2012. Leukaemia and Lymphoma 53(7): 1251-2 IF: 2.3
  9. Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino ACW. Prospective histomorphometric and DXA evaluation of bone remodelling in imatinib-treated CML patients: evidence for site-specific skeletal effects. 2012. Journal of Clinical Endocrinology and Metabolism 98:67-76 IF: 6.43

2011

  1. Engler JR, Hughes TP, White DL. OCT-1 as a Determinant of Response to Antileukemic Treatment. 2011. Clinical Pharmacology and Therapeutics 89(4): 608-11 IF: 6.85
  2. Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? 2011. Leukemia 25(2):193-200 IF: 10.16
  3. Engler JR, Zannettino ACW, Bailey CG, Rasko JEJ, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. 2011. Haematologica 96:213-220 IF: 5.94
  4. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White DL, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia. 2011. Blood 118:3634-3644 IF: 9.06
  5. Parker W, Prime J, Ho M, Irwin DL, Scott H, Hughes TP, Branford S. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukaemia after imatinib resistance is predictive of outcome during subsequent therapy. 2011. Journal of Clinical Oncology 29(32)4250-4259 IF: 18.04
  6. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP. Hochhaus A. BCR-ABL transcripts dynamics support the hypothesis that leukaemic stem cells are reduced during imatinib treatment. 2011. Cancer Research 17(21): 1-10 IF: 8.65
  7. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukaemia response to long-term targeted therapy reveal treatment effects of leukaemic stem cells. 2011. Blood 118:1622-1631 IF: 9.06
  8. Hercus T, Broughton S, Ekert H, Ramshaw M, Grimbaldeston M, Perugini M, Woodcock J, Thomas D, Pitson S, Hughes TP, D’Andrea R, Parker M, Lopez A. The GM-CSF receptor family: mechanism of activation and implications for disease. 2011. Growth Factors 30(2):63-75 IF: 2.2
  9. Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. 2011. Leukemia and Lymphoma 52:2139-2147 IF: 2.3
  10. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. 2011. Current Hematological Malignancy Reports 6:88-95 IF: 1.85
  11. Yeung DT, White DL. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all? 2011. Leukemia & Lymphoma 52:165. IF: 2.3

2010

  1. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW. Dysregulation of bone remodelling by imatinib mesylate. 2010. Blood 115:766-774 IF: 9.06
  2. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. 2010. Leukemia 24: 658-660 IF: 10.16
  3. Eadie L, Hughes T, White DL. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. 2010. Leukemia 24:855-857 IF: 10.16
  4. Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. 2010. Blood 116:2776-2778 IF: 9.06
  5. Engler JR, Frede A, Saunders VA, Zannettino AC, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. 2010. Leukemia 24:765-770 IF: 10.16
  6. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? 2010. Journal of Clinical Endocrinology & Metabolism 95:3763-3767 IF: 6.43
  7. Hiwase D, White D, Powell JA, Saunders VA, Zrim S, Frede A, Guthridge MA, Lopez AF, D'Andrea RJ, To LB. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. 2010. Leukemia 24:771-778 IF: 10.16
  8. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. 2010. International Journal of Hematology 32(6 Pt1):222-228 IF: 1.68
  9. Fraser C, Brown M, Diener K, Guerin L, Hughes TP, Lousberg ER, Hayball JD. Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. 2010. Cancer Biology & Therapy 10(7): 715-727 IF: 3.29
  10. Ross DM, Branford S, Seymour JF, Schwarer AP, Aruthur A, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills A K, Grigg AP, Melo J, Hughes TP. Patients with chronic myeloid leukaemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukaemia by DNA PCR. 2010. Leukemia 24: 1719-1724 IF: 10.16
  11. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. 2010. Journal of Clinical Oncology 28:2761-2767 IF: 18.04
  12. White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. 2010. Leukemia 24:1962-1965 IF: 10.16

2009

  1. Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. 2009. Journal of Cellular and Molecular Medicine 13(3): 599-601 IF: 4.75
  2. Viswanathan S, Powers JT, Einhorn W, Hoshida Yujin, Ng T, Toffanin S, O’Sullivan M, Lu J, Philips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 enhances tumorigenesis and is associated with advanced human malignancies. 2009. Nature Genetics 41(7): 843-8 IF: 35.2
  3. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, Zannettino ACW. Imatinib mesylate causes growth plate closure in-vivo. 2009.Leukemia 23(11): 2155-2159 IF: 10.16
  4. Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP.Short term intense BCR-ABL kinase inhibition with Nilotinib is adequate to trigger cell death in BCR-ABL+ cells. 2009.Leukemia 23: 1205-1206 IF: 10.16
  5. Ross DM, Schfranek L, Hughes TP, Nicola M, Branford S, Score J. Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification. 2009.Cancer Genetics and Cytogenetics 189(2): 138-9 IF: 1.9
  6. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener K, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. 2009.Experimental Hematology 37(12): 1435-44 IF: 2.9
  7. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo. 2009. Experimental Haematology 37(2): 256-265 IF: 2.9
  8. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, Zannettino AC. Therapeutic concentrations of dasatinib inhibit in vitro osteclastogenesis. 2009. Leukemia 23(5): 994-7 IF: 10.16
  9. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. 2009. Leukemia 24:658-660 IF: 10.16

Get in touch
+61 8 8128 4000 info@sahmri.com
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.